Press release
Akt/Protein Kinase B (PKB) Inhibitors to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top Key Players Roche, Eli Lilly and Company, Merck, Novartis, Denovo Biopharma, Diffusion Pharmaceuticals, Astex Therapeutics, ArQu
Download the sample report @ https://www.pharmaproff.com/request-sample/1154
Akt plays a critical role in the regulation of cell’s apoptotic pathway and it is being studied extensively for targeting cancerous cells. Akt inhibitors are therapeutics that obstruct the Akt pathways or Akt enzyme, which play a key role in proliferation of solid tumors or cancer cells. Akt are composed of various AGC kinases present in the cells that have hydrophobic motif at the c-terminus of their catalytic core.
Get the detailed analysis @ https://www.pharmaproff.com/report/pkb-inhibitors-pipeline-analysis
According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by the oral route. It has been observed that oral route of medications is convenient; available in delayed or rapid release formulation; provides improved patient’s compliance; less risk of systemic infections; and has inexpensive nature. Akt inhibitors through oral route of administration have shown positive results in the clinical studies.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1154
The companies who are developing Akt/PKB inhibitors for the treatment of various chronic diseases have shown positive clinical results in the various phases of drug development. For instance, in June 2018, F. Hoffman-La Roche Ltd. announced the interim results of Phase II study (LOTUS) for the drug candidate, ipatasertib, that showed improvement in patients with triple negative breast cancer (TNBC) toward overall survival (OS). This result was presented in the 2018 ASCO Annual Meeting, held in the U.S. The Phase II LOTUS study showed an increase in OS up to 23.1 months (median) in interventional study, as compared to 18.4 months (median) in placebo study.
Some of the key players involved in the development of Akt/PKB inhibitors include F. Hoffman-La-Roche Ltd, Eli Lilly & Company, Merck & Co. Inc., Novartis AG, Denovo Biopharma LLC, Diffusion Pharmaceuticals Inc., Astex Pharmaceuticals, ArQule Inc., Cotinga Pharmaceuticals Inc., and Oneness Biotech Co. Ltd.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Akt/Protein Kinase B (PKB) Inhibitors to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top Key Players Roche, Eli Lilly and Company, Merck, Novartis, Denovo Biopharma, Diffusion Pharmaceuticals, Astex Therapeutics, ArQu here
News-ID: 1674888 • Views: …
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.
IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to…
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome.
Download the sample report at: https://www.pharmaproff.com/request-sample/1189
Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in…
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances…
More Releases for Akt
On-demand Fitness Market Size And Forecast | Forte, AKT, NEOU, CorePower Yoga, B …
New Jersey, United States - The research study offers an in-depth assessment of the On-demand Fitness Market and helps market players to gain a foothold in the industry. It highlights critical market dynamics such as drivers, restraints, trends, and opportunities to help businesses prepare for the challenges ahead. It provides a regional analysis of the On-demand Fitness market to uncover major opportunities available in different parts of the world. The…
Global Akt Antibody Market Report 2021: Top 5 Players Captured 71% Share in 2020 …
The Global Akt Antibody Market Report makes available the current and forthcoming technical and financial details of the industry. The report contains an in-depth analysis of market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape. This report explores all the key factors affecting the growth of the global market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis. The study involves the extensive usage…
Asia-Pacific Emergency Lighting Market 2017- 2022: , Acuity Brands, NVC, Ventilu …
Asia-Pacific Emergency Lighting Market Report 2017 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing capital structure of the Asia-Pacific Emergency Lighting Market.
Get Access to sample pages @ https://www.htfmarketreport.com/sample-report/795936-asia-pacific-emergency-lighting-market-3
Asia-Pacific Emergency Lighting market competition by top manufacturers, with…
AKT Inhibitors - Pipeline Insights 2017
The “AKT Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of AKT drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential AKT inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and…
AKT-ZENT International Theatre Centre becomes World Theatre Training Institute A …
The AKT-ZENT International Theatre Centre in Berlin, which was appointed Research Centre of the International Theatre Institute (ITI) in 2011, is moving ahead: it will become an Institute for research into innovative theatre training methods and pedagogical techniques for professional theatre and their wider application in all areas of society.
This appointment by the ITI and the relaunch recognises the longstanding research excellence of artistic director Dr Jurij Alschitz and…
AKT Inhibitors - Pipeline Insights 2017
The “AKT Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of AKT drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential AKT inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and…
